...has its fingers the pulse in the fight against bacteria. The company is developing new formulations of existing antibiotics that are no longer patent protected, using its PULSYS once-a-day pulsatile delivery technology. Among the antibiotics that the company is researching are amoxicillin, cephalexin, and clarithromycin. Advancis is looking to collaborate with other drugmakers to use its PULSYS technology; the company already has made a deal with Eli Lilly to develop a PULSYS version of its Keflex brand of cephalexin, and in the meantime it handles the sales and marketing of Keflex in the US. HealthCare Ventures owns 37% of Advancis.

Shares were up 8% after reaching an agreement...

NOTE: All illustrations and photos have been removed from this article.



More articles from M2 Presswire
Market Commentary on CuraGen Corp., February 28, 2007
Supanet aiming for web hosting revolution., February 28, 2007
National Guard (In Federal Status) And Reserve Mobilized As Of Februar..., February 28, 2007
DISH Network and emuse absolutely offer ground-breaking interactive co..., February 28, 2007
In- Depth Research on Syntroleum Corp., February 28, 2007

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.